
Stattic
CAS No. 19983-44-9
Stattic( STAT3 Inhibitor V )
Catalog No. M13121 CAS No. 19983-44-9
Stattic, the first nonpeptidic small molecule, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM, highly selectivity over STAT1.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
10MG | 42 | In Stock |
![]() ![]() |
25MG | 69 | In Stock |
![]() ![]() |
50MG | 113 | In Stock |
![]() ![]() |
100MG | 177 | In Stock |
![]() ![]() |
200MG | 264 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameStattic
-
NoteResearch use only, not for human use.
-
Brief DescriptionStattic, the first nonpeptidic small molecule, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM, highly selectivity over STAT1.
-
DescriptionStattic, the first nonpeptidic small molecule, potently inhibits STAT3 activation and nuclear translocation with IC50 of 5.1 μM, highly selectivity over STAT1.(In Vitro):Stattic (20 μM; 24 hours) inhibits STAT3 phosphorylation (Y705) and selectively inhibits P-STAT3 as demonstrated by the lack of inhibition of P-ERK1/2 in ALDH+ and D44+/CD24+ subpopulations of Panc-1 and HPAC pancreatic cancer cell lines.Stattic (2.5, 5, 10 μM; for 4 h) significantly reduces the nuclear level of pSTAT3 and survivin in PC3M-1E8 cells at 10 μM. Stattic (2.5-10 μM; for 24 h) inhibits IL-6-induced STAT3 activation in a dose-dependent manner.Stattic (2.5, 5, 10 μM; for 48 h) suppresses both the growth and induces apoptosis prostate cancer cells (PC3M-1E8 cells) with 10 μM. Stattic does not induce significant cell apoptosis with 2.5 μM, 5 μM.Stattic (2.5, 5, 10 μM; for 48 h) shows significant S phase accumulation.Stattic can not lead to significant morphological changes or apoptosis and has little STAT3 phosphorylation in A2780 cells and HUVECs.(In Vivo):Stattic (10 mg/kg; i.p.; three times per week for 10 week) ameliorates the renal dysfunction in Alport syndrome (AS) mice.
-
In Vitro——
-
In VivoAnimal Model:Age-matched wild-type (WT) C57BL/6 miceDosage:10 mg/kg Administration:IP; three timesper week for 10 week Result:Increased levels of proteinuria, BUN and serum creatinine.Significantly suppressed the gene expression levels of renal injury markers (Lcn2, Kim-1), pro-inflammatory cytokines (Il-6, KC), pro-fibrotic genes (Tgf-β, Col1a1, α-Sma) and Mmp9.
-
SynonymsSTAT3 Inhibitor V
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT3
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number19983-44-9
-
Formula Weight211.19
-
Molecular FormulaC8H5NO4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 42 mg/mL (198.87 mM)
-
SMILESO=[N+](C1=CC=C(C2=C1)C=CS2(=O)=O)[O-]
-
Chemical Name6-Nitro-1-benzothiophene 1,1-dioxide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Schust J, et al. Chem Biol, 2006, 13(11), 1235-1242.
molnova catalog



related products
-
LLL-12
A nonpeptide, cell-permeable STAT3 inhibitor that binds directly to the pTyr705 binding site of the STAT3 monomer.
-
InS3-54A18
InS3-54A18 is an active analog of inS3-54 targeting the DBD of STAT3 with IC50 of 8.8 uM in STAT3-dependent luciferase reporter assay.
-
BTA-9881
BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.